Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Feb. 26, 2026	Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)	R&D
Feb. 26, 2026	Termination of License Agreement for Selective Orexin 2 Receptor Agonist DSP‑0187	Licensing
Feb. 20, 2026	Launch of Joint Research on a Novel Multi-Stage Malaria Vaccine by Ehime University and Sumitomo Pharma and Grant Award from the GHIT Fund	R&D
Feb. 19, 2026	Posted R&D Meeting [Webcast]	R&D
Feb. 17, 2026	Posted Presentation Material (R&D Meeting)（PDF/2,493KB）	R&D
Feb. 13, 2026	Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY)	Products

May 13, 2026	FY2025 financial results announcement (scheduled to be disclosed at 1:00 p.m.), conference on financial results FY2025 for Analysts, Investors, and the Press